GET DAILY SIGNALSWhy Is Xeris Biopharma Holdings (XERS) Stock Up +22.18% Today?
Key Takeaways
- XERS shares surged roughly 22.18% on Thursday, jumping from a prior close of $10.46 to around $12.78.
- The primary catalyst was a strong third-quarter 2026 earnings report that beat analyst expectations on both earnings and revenue.
- Management raised its full-year 2026 revenue guidance and lifted its long-term 2030 revenue outlook to more than $1 billion.
- Sales of its lead drug Recorlev nearly doubled year over year, driving record quarterly revenue and a swing to GAAP profitability.
- The stock reached a new 52-week high as broader biotech sentiment remained constructive.
- Traders are now watching fourth-quarter momentum, the Recorlev launch trajectory, and the start of the XP-8121 Phase 3 study.
- For deeper insight into this stock's valuation and outlook, explore Price Targets, Earnings, and Forecast pages.
- Discover how AI-driven strategies are navigating moves like this one on the Trending AI Robots page.
Opening Summary
Xeris Biopharma Holdings, Inc. (XERS), a Chicago-based commercial-stage biopharmaceutical company focused on endocrine and rare diseases, delivered one of its strongest single-day rallies in recent history on Thursday. The stock climbed approximately 22.18%, rising from a previous close of $10.46 to trade near $12.78 intraday and touching a fresh 52-week high. The earnings-driven move followed the company's third-quarter 2026 results, which topped Wall Street forecasts and prompted management to raise its near- and long-term financial outlook. Markets attributed the sharp advance to accelerating revenue growth, a swing to profitability, and an upgraded long-term growth trajectory anchored by the company's Cushing's syndrome therapy, Recorlev.
Earnings Results and Guidance
The defining catalyst for the price rally was Xeris' third-quarter report. The company posted diluted earnings per share of $0.06, well ahead of the roughly $0.03 consensus estimate, and revenue of $107.2 million, up 44% year over year and above the approximately $101.6 million analysts had projected. GAAP net income swung to $11.3 million from $0.6 million in the prior-year period, while adjusted EBITDA climbed 77% year over year to $30.8 million. Gross margin expanded to 88% from 85%, reflecting a favorable product mix.
Guidance reinforced the bullish tone. Management raised its full-year 2026 revenue outlook to $395 million to $405 million, up from a prior range of roughly $385 million to $390 million, and lifted its 2030 total revenue target to more than $1 billion from about $750 million previously. Chief Executive Officer John Shannon said the results put the company "on a new growth curve," framing the momentum as broad-based rather than a single-quarter spike.
Recorlev Momentum Drives the Story
Much of the upside centered on Recorlev, the company's cortisol synthesis inhibitor for endogenous Cushing's syndrome. Recorlev net revenue reached $71.5 million in the quarter, a 93% jump year over year and a 26% sequential increase. Management now sees Recorlev on a path toward nearly $1 billion in annual net revenue three to four years sooner than previously expected, a key reason investors re-rated the shares. Keveyis, the company's therapy for primary periodic paralysis, rose 9% year over year for its fourth consecutive quarter of growth, with a newly issued patent expected to extend protection through at least 2043.
Gvoke, the ready-to-use glucagon product for severe hypoglycemia, was a partial offset, with net revenue down 14% to $21.7 million. The decline reflected a one-time $4 million gross-to-net adjustment in the Medicaid channel, while underlying prescription demand still grew 5% year over year. Investors largely looked past this item, treating it as transitory.
Pipeline and Corporate Developments
The advance was also supported by progress on XP-8121, the company's Phase 3-ready, once-weekly subcutaneous levothyroxine candidate for hypothyroidism. Management reiterated plans to initiate the pivotal Cornerstone study before year-end, with a third U.S. patent granted in October extending patent protection to 2043. A strengthened balance sheet added to the constructive backdrop: Xeris retired its remaining 8% convertible senior notes due 2028 in July, eliminating roughly $34 million of debt and about $3 million in annual interest expense, while cash and equivalents stood at $131.1 million at quarter-end.
Market Context and Trading Activity
Trading activity reflected strong conviction in the results. Volume ran well above typical levels as the stock broke decisively above its prior 52-week high, clearing a level not seen in years and confirming a technical breakout. The move was idiosyncratic and earnings-driven rather than a product of broad index strength, though a generally supportive backdrop for small- and mid-cap biotech likely amplified the rally. The sharp gap higher and sustained bid suggest both momentum and fundamental repositioning among investors responding to the upgraded guidance.
What Comes Next for XERS
Investors will now track whether the company's fourth-quarter revenue can extend the sequential acceleration implied by its raised guidance, which points to roughly $112 million to $123 million in Q4 revenue. Key watchpoints include continued Recorlev launch execution, Gvoke's return to underlying growth, and the timely initiation of the XP-8121 Cornerstone study. Risks remain: SG&A expense growth is elevated as the company expands its commercial footprint, Recorlev access remains prior-authorization intensive, and the long-term outlook leans heavily on continued success of a single franchise. Any stumble in commercial momentum or pipeline timing could test the newly elevated valuation.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are currently performing at the top of their class. Tickeron offers hundreds of these automated bots covering thousands of tickers, but only the strongest performers under prevailing market conditions are featured in this section. Each bot varies by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. If you're interested in seeing how AI-driven strategies are navigating the market today, consider browsing the Trending AI Robots section.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XERS's Stochastic Oscillator is sitting in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where XERS advanced for three days, in 223 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 188 of 232 cases where XERS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for XERS moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 31 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XERS as a result. In 61 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for XERS turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 33 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XERS's P/B Ratio (-195.918) is very low in comparison to the industry average of (7.659). XERS has a moderately low P/E Ratio (-104.600) as compared to the industry average of (0.330). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.196) is also within normal values, averaging (181.047).
The Tickeron Seasonality Score of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 23 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. XERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of ready-to-use, liquid-stable injectables
Industry PharmaceuticalsGeneric
Advertisement